News from cti A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 09, 2014, 01:30 ET

CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells

CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced data showing treatment with pacritinib, an investigational oral multikinase...

Dec 06, 2014, 12:00 ET

CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers

 CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that an analysis of kinase inhibition by pacritinib, a next generation oral...

Dec 04, 2014, 01:30 ET

CTI BioPharma Receives $15 Million Milestone Payment for TRISENOX®

 CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received a $15 million milestone payment from Teva Pharmaceutical...

Dec 01, 2014, 01:30 ET

CTI BioPharma Announces Data Presentations at the 56th American Society of Hematology Annual Meeting

CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the upcoming presentations of data highlighting pacritinib, an oral multikinase...

Nov 17, 2014, 01:30 ET

CTI BioPharma to Present at the Upcoming Investor Conferences

 CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today management will present at the following upcoming investor...

Nov 07, 2014, 09:15 ET

CTI BioPharma Prices Underwritten Public Offering of $35 Million of Convertible Preferred Stock

CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 35,000 shares of its Series 21...

Nov 06, 2014, 16:15 ET

CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock

CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions,...

Oct 29, 2014, 16:01 ET

CTI BioPharma Reports Third Quarter 2014 Financial Results

CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the three months ended September 30, 2014. "During the...

Oct 27, 2014, 02:30 ET

CTI Acquires Exclusive Worldwide License to Tosedostat, a Selective Oral Anti-Cancer Therapy

CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that it has acquired worldwide rights to tosedostat through concurrent...

Oct 20, 2014, 01:30 ET

CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014

CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its third quarter 2014 financial results on Wednesday, October...

Sep 17, 2014, 01:30 ET

CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI®

 CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) and Servier today jointly announced that they have entered into an exclusive license and...

Aug 07, 2014, 01:30 ET

FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis

CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S....

Aug 04, 2014, 16:01 ET

CTI BioPharma Reports Second Quarter 2014 Financial Results

CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the second quarter and six months ended June 30, 2014. "In...

Jul 28, 2014, 01:30 ET

CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014

CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its second quarter 2014 financial results on Monday, August 4,...

Jul 21, 2014, 01:30 ET

CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In The Netherlands

CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it has received approval from the Israeli Ministry of Health (MOH) for...

Jul 01, 2014, 01:30 ET
CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis

 CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that it has completed recruitment in the PERSIST-1 pivotal...

Jun 12, 2014, 01:30 ET
CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Initiates Randomized Phase 2 Trial Evaluating Tosedostat plus Cytarabine for Older Patients with AML or High-Risk MDS

CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of...

Dec 11, 2013, 08:40 ET
CTI logo.  (PRNewsFoto/CTI)

CTI GSA Products Showcased at the MA Police Accreditation Conference

Computech International (CTI), a GSA products provider, was one of several vendors at the Massachusetts Police Accreditation conference on law...

Dec 04, 2013, 08:35 ET
CTI Store Logo.  (PRNewsFoto/CTI)

NETGEAR Platinum Partner CTI Launches NETGEAR Switches Product Page

GSA Contracts holder CTI recently launched a new page on its website featuring NETGEAR switches currently offered by the company. The newly added...

Aug 23, 2013, 08:45 ET
CTI Logo.  (PRNewsFoto/CTI)

CTI Now Offers Panasonic Toughbook Service to Maximize Product Performance

 Computech International (CTI), a comprehensive technology solutions provider with over 60,000 GSA products, is proud to offer customized...